BEXIMCO PHARMACEUTICALS LTD.
12 November 2020
Open pledge to fight COVID-19
Beximco Pharmaceuticals Ltd. signed the Open pledge from Global Manufacturers of Generic Medicines against COVID-19
Beximco Pharmaceuticals Ltd. is very proud to join other leading pharmaceutical manufacturing companies from around the world in this global initiative to support the fight against COVID-19. By signing the Open pledge from Global Manufacturers of Generic Medicines against COVID-19, Beximco Pharmaceuticals Ltd. affirms its engagement and offers its capacity to develop and supply COVID-19 treatments - re-purposed, new, small molecules and biologics - to those in need. Through the pledge, we commit to work with the Medicines Patent Pool (MPP) in making COVID-19 treatments available especially in low- and middle-income countries, complementing the efforts of originators. And by doing so, we support SUCCESS (Sustainable Universal access through Collaboration, Coordination, Emergency measures, Scale and Speed).
One thread that connects us all - the first signees of this pledge - is the work that we have done with the UN-backed MPP and many other partners in making billions - precisely 15 billion doses - of life-saving HIV and hepatitis C medicines available and affordable in low- and middle-income countries.
All together, we represent a large proportion of the world’s generic industry and the pledge is set to gain strength as additional manufacturer, supplier and distributor can join the effort. Collectively, we will bring to the table capacity to deliver substantial amounts of conventional drugs, technically known as “small molecules”, and an increasing ability to produce new, more complex interventions known as biologics.